Loading...
•
Dec 31, 2023
Lineage Q4 2023 Earnings Report
Lineage reported fourth quarter and full year results, highlighting progress in clinical programs and a strengthened financial position.
Key Takeaways
Lineage Cell Therapeutics reported Q4 2023 revenues of $2.1 million and a net loss of $4.8 million, or $0.03 per share. The company's cash, cash equivalents, and marketable securities totaled $35.5 million as of December 31, 2023, expected to support operations into Q3 2025.
Advanced OpRegen for Dry AMD in Phase 2a study in collaboration with Roche and Genentech.
Closed $14 Million Registered Direct Offering.
OPC1 Investigational New Drug Amendment Cleared; New Clinical Trial Planned.
Initiated Development of Hypoimmune iPSC Cell Line for Neurology Indications Under Gene Editing Collaboration with Eterna Therapeutics.
Lineage
Lineage
Lineage Revenue by Segment
Revenue by Segment
Royalties & Licensing Revenue
CapyFin.com Forward Guidance
Lineage anticipates continued advancement of its clinical programs, supported by a strengthened balance sheet, with cash runway expected into Q3 2025.
Positive Outlook
- Continued execution under collaboration with Roche and Genentech for OpRegen.
- INDa clearance for OPC1, enabling initiation of DOSED clinical study.
- Positive ANP1 initial proof of concept results from collaboration with the University of Michigan.
- Initiated development activities for hypoimmune pluripotent cell line for neurology indications under collaboration with Eterna Therapeutics.
- Cash, cash equivalents, and marketable securities expected to support planned operations into Q3 2025.
Challenges Ahead
- Clinical trials may not commence, progress, or be completed as expected.
- Positive findings in early studies may not predict success in subsequent studies.
- OpRegen may not provide durable improvements in dry-AMD patients.
- Competing therapies may adversely impact the commercial potential of OpRegen.
- Roche and Genentech may not successfully advance OpRegen or obtain regulatory approval.